Indivior settles patent litigation with Dr. Reddy’s
Indivior
968.00p
12:40 24/12/24
2.22%
21.00p
Opioid addiction treatment maker Indivior has settled a patent infringement case with generic drug maker Dr. Reddy’s Laboratories.
FTSE 250
20,571.51
13:00 24/12/24
n/a
n/a
FTSE 350
4,491.87
12:54 24/12/24
n/a
n/a
FTSE All-Share
4,449.61
13:14 24/12/24
n/a
n/a
Pharmaceuticals & Biotechnology
20,055.90
12:54 24/12/24
0.25%
50.73
The settlement related to Dr. Reddy’s generic buprenorphine and naloxone sublingual film, which is a therapeutic equivalent generic version of Indivior’s Suboxone sublingual film.
"The confidential settlement resolves all claims between the parties and the amount paid by Indivior to DRL pursuant to the settlement is consistent with its previously disclosed reserve amount," the company said.